This article was last updated January 7, 2021.
In early 2020, as the novel coronavirus spread rapidly across the globe, biopharmaceutical researchers turned to face the challenge head on. Given the pressing need for safe and effective vaccines to help prevent COVID-19, along with the volume of information that remained unknown about the disease, a wide range of approaches to vaccine development were used to improve the odds that one or more of these approaches would be successful.
“By no means have the last few months been business as usual,” said Advait Badkar, Ph.D., Senior Director, Novel Delivery Technologies at Pfizer, which is one of numerous companies researching a potential COVID-19 vaccine. “We’ve all stepped up to meet this challenge.”